Trials / Unknown
UnknownNCT04891653
A Phase I Study of BR790 in Subjects With Advanced Solid Tumors
A Open-label, Multi-center Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and Efficacy of BR790 Monotherapy in Subjects With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study was to evaluate the safety and tolerability of BR790 tablets as an oral monotherapy in subjects with advanced solid tumors, and to determine dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and/or recommended phase II clinical trial dose (RP2D) .The study is divided into two phases: dose escalation phase and dose expansion phase.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BR790 | Subjects will receive oral administration of BR790. |
Timeline
- Start date
- 2021-06-30
- Primary completion
- 2023-06-30
- Completion
- 2023-12-31
- First posted
- 2021-05-18
- Last updated
- 2021-05-18
Source: ClinicalTrials.gov record NCT04891653. Inclusion in this directory is not an endorsement.